These may include the use of BCMA-targeting CAR-T cells and bispecific antibodies, which have shown fast, deep responses in patients with refractory MM [23], as well as CAR-T and bispecific antibodies targeting against other antigens, such as GPRC5D. The gene discussed is GPRC5D; the disease is Miyoshi myopathy.